Preclinical studies demonstrate analgesic effects of RvD1 in managing pain, suggesting a safer alternative to traditional medications.
Pain is a protective mechanism of the body that is intensified during inflammatory processes through the sensitization of nociceptive neurons. Although current drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and opioids, are effective, their side effects reinforce the search for safer alternatives. In this context, studies investigating the analgesic effects of specialized pro-resolving mediators (SPMs), derived from polyunsaturated fatty acids, stand out. Resolvin D1 (RvD1), derived from the omega-3 fatty acid docosahexaenoic acid, acts in a multimodal manner to modulate pain and inflammation by regulating immunological, neuronal, and glial responses. Thus, RvD1 is a promising molecule for resolving inflammatory and painful processes. Herein, we address the main analgesic mechanisms of RvD1 in different preclinical models.
No takes yet. Share an insight, caveat, or question.
Martelossi-Cebinelli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: